

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SBI HOLDINGS, INC.

(Incorporated in Japan with limited liability)

(Stock code: 6488)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached copy of the Announcement.

On behalf of the Board

SBI Holdings, Inc.

Yoshitaka Kitao

Chief Executive Officer

Japan, 30 March 2012

As of the date of this announcement, the executive Directors are Mr Yoshitaka Kitao, Mr Taro Izuchi, Mr Takashi Nakagawa, Mr Kenji Hirai, Mr Tomoya Asakura, Mr Takashi Okita, Mr Noriaki Maruyama, Mr Shumpei Morita, Mr Shinji Yamauchi, Mr Makoto Miyazaki, Mr Yoshimi Takahashi and Mr Masaki Takayanagi, the non-executive Directors are Mr Yasutaro Sawada, Mr Hiroyoshi Kido, Mr Noriyoshi Kimura and Mr Hiroshi Tasaka and the independent non-executive Directors are Mr Masaki Yoshida, Mr Kiyoshi Nagano, Mr Keiji Watanabe, Mr Takeshi Natsuno and Mr Akihiro Tamaki.

March 30, 2012

SBI Holdings, Inc.

(TOKYO: 8473 / Hong Kong: 6488)

Notice on Partial Transfer of Subsidiary Shares and the Resulting Extraordinary Income

SBI Holdings, Inc. (“SBIH”) hereby announces that it will transfer some of the shares its subsidiary holds in consolidated subsidiary SBI ALApromo Co, Ltd. (the company name is to be changed to SBI Pharmaceuticals Co., Ltd. on April 1, 2012; head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”). The shares will be transferred to multiple third parties. SBIH is expected to book an extraordinary income as a result of this share transfer.

1. Reasons for the transfer

SBI ALApromo, which obtained First-class Marketing Authorization in February 2012, is actively engaged in research and development of medicines, cosmetics and health foods using 5-aminolevulinic acid (ALA)* as a pharmaceutical company. As SBI ALApromo plans to accelerate development of new drugs utilizing ALA, the proceeds from this transfer will be allocated primarily for prior investments in the business. The transferees of the shares were determined in consideration of their ability to contribute to future growth of ALA businesses in various aspects.

2. Status of shares held by the SBI Group before and after the share transfer

- (1) Holding ratio before the transfer 79.15%
- (2) Holding ratio after the transfer 73.32%

3. Future outlook

As a result of this transfer, consolidated extraordinary income of approximately 4.2 billion yen is expected to be recorded for the fiscal year ending March 2012.

* About 5-aminolevulinic acid (ALA):

An amino acid created in mitochondria. It is an important substance that serves as protein material related to energy production in the form of hemes and cytochromes, and its productivity is known to decrease with age. ALA is contained in *shochu* distillation remnants, red wine and food such as radish sprouts. It is also known as a material forming chloroplasts in plants.

For further information, please contact:

SBI Holdings, Inc. Corporate Communications Dept., Tel: +81 3 6229 0126